Drugs / ADCE-T02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06597721 | Nov 2024 → Mar 2027 expected | neoplasm | Adcendo ApS | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-23 | Adcendo ApS | Results Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting adcendo.com ↗
ADCE-T02 shows strong anti-tumor activity in a wide range of solid tumor models and is well tolerated in non-human primate toxicology studies with no evidence of toxicity from earlier generation TF ADCs. |
| 2025-02-26 | Adcendo ApS | Regulatory Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02 adcendo.com ↗
Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that the U.S. Food & Drug Administration (FDA) has provided clearance of the IND application for a Phase I study evaluating ADCE-T02 in patients with advanced solid tumors. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADCE-T02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06597721 ↗ |
| Known as | AMT-754 | “Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may...” NCT06597721 ↗ |
| Modality | Monoclonal antibody | “ADCE-T02 is a novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the Topoisomerase-1 inhibitor Exatecan at an average...” PMID 41996633 ↗ Apr 2026 |
| Route | Intravenous | “Administered intravenously” NCT06597721 ↗ |